| 2.08 -0.01 (-0.48%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.43 |
1-year : | 2.45 |
| Resists | First : | 2.08 |
Second : | 2.09 |
| Pivot price | 2.08 |
|||
| Supports | First : | 2.06 |
Second : | 1.71 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.08 |
| MA(100) : | 2.16 |
MA(250) : | 2.77 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 74 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 4.73 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MURA ] has closed above bottom band by 27.4%. Bollinger Bands are 87.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.1 - 2.11 | 2.11 - 2.12 |
| Low: | 2.05 - 2.06 | 2.06 - 2.08 |
| Close: | 2.06 - 2.08 | 2.08 - 2.1 |
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Fri, 24 Oct 2025
Mural Oncology Approves Acquisition by XRA 5 Corp. - TipRanks
Fri, 24 Oct 2025
Mural Oncology (NASDAQ: MURA) gets 99% approval for XRA 5 deal; base $2.035/share - Stock Titan
Wed, 20 Aug 2025
Mural Oncology to be Acquired by XRA 5 - citybiz
Wed, 20 Aug 2025
Mural Oncology plc enters acquisition agreement with XRA 5 Corp (XOMA Royalty Corporation) - Arthur Cox LLP
Wed, 20 Aug 2025
XOMA Royalty to acquire Mural Oncology for up to $2.24 per share - Investing.com
Wed, 20 Aug 2025
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 13.4 (%) |
| Held by Institutions | 59 (%) |
| Shares Short | 426 (K) |
| Shares Short P.Month | 559 (K) |
| EPS | -8.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.6 % |
| Return on Equity (ttm) | -111.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -130 (M) |
| Levered Free Cash Flow | -74 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | 0.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|